

Pfizer Inc.

Estring.....5-6

Sepracor Inc.

LunestaIBC, OBC

Wyeth Pharmaceuticals

PremproIFC, 1-3

**Position Statement, Part 2:
The Role of Testosterone Therapy in
Post-menopausal Women: Position
Statement of The North American
Menopause Society**

(continued from page 26)

36. Shifren JL, Braunstein GD, Simon JA, et al. Transdermal testosterone treatment in women with impaired sexual function after oophorectomy. *N Engl J Med* 2000;343:682-688.

37. Braunstein GD, Sundwall DA, Katz M, et al. Safety and efficacy of a testosterone patch for the treatment of hypoactive sexual desire disorder in surgically menopausal women: a randomized, placebo-controlled trial. *Arch Intern Med* 2005;165:1582-1589.

38. Buster JE, Kingsberg SA, Aguirre O, et al. Testosterone patch for low sexual desire in surgically menopausal women: a randomized trial. *Obstet Gynecol* 2005;105:944-952.

39. Miller B, De Souza M, Slade K, Lucciano AA. Sublingual administration of micronized estradiol and progesterone, with and without micronized testosterone: effect on biochemical markers of bone metabolism and bone mineral density. *Menopause* 2000;7:318-326.

40. Watts NB, Notelovitz M, Timmons MC, Addison WA, Wiita B, Downey LJ. Comparison of oral estrogens and estrogens plus androgen on bone mineral density, menopausal symptoms, and lipid-lipoprotein profiles in surgical menopause. *Obstet Gynecol* 1995;85:529-537.

41. Raisz LG, Wiita B, Artis A, et al. Comparison of the effects of estrogen alone and estrogen plus androgen on biochemical markers of bone formation and resorption in postmenopausal women. *J Clin Endocrinol Metab* 1995; 81:37-43.

42. Garnett T, Studd J, Watson N, Sawvas M, Leather A. The effects of plasma estradiol levels on increases in vertebral and femoral bone density following therapy with estradiol and estradiol with testosterone implants. *Obstet Gynecol* 1992;79:968-972.

43. Barrett-Connor E, Young R, Notelovitz M, et al. A two-year, double-blind comparison of estrogen-androgen and conjugated estrogens in surgically menopausal women: effects on bone mineral density, symptoms and lipid profiles. *J Reprod Med* 1999;44:1012-1020.

44. Montgomery J, Appleby L, Brincat M, et al. Effect of oestrogen and testosterone implants on psychological disorders in the climacteric. *Lancet* 1987;1:297-299.

45. Regestein Q, Friebely J, Shifren J, Schiff I. Neuropsychological effects of methyltestosterone in women using menopausal hormone replacement. *J Womens Health Gend Based Med* 2001;10:671-676.

46. Sherwin BB, Gelfand MM. Differential symptom response to parenteral estrogen and/or androgen administration in the surgical menopause. *Am J Obstet Gynecol* 1985;151:153-160.

47. Greene JG, Cooke D. Life stress and symptoms at the climacterium. *Br J Psychiatry* 1980;136:486-491.

48. Hilditch JR, Lewis J, Peter A, et al. A menopause-specific quality of life questionnaire: development and psychometric properties [published erratum appears in: *Maturitas* 1996;25:231]. *Maturitas* 1996;24:161-175.

49. Basaria S, Nguyen T, Rosenson RS, Dobs AS. Effect of methyl testosterone administration on plasma viscosity in postmenopausal women. *Clin Endocrinol (Oxf)* 2002;57:209-214.

50. Dobs AS, Nguyen T, Pace C, Roberts CP. Differential effects of oral estrogen versus estrogen-androgen replacement therapy on body composition in postmenopausal women. *J Clin Endocrinol Metab* 2002;87:1509-1516.

51. Farish E, Fletcher CD, Hart DM, Azzawi FA, Abdalla HI, Gray CE. The effects of hormone implants on serum lipoproteins and steroid hormones in bilaterally oophorectomized women. *Acta Endocrinol (Copenh)* 1984;106:116-120.

52. Hickok LR, Toomey C, Speroff L. A comparison of esterified estrogens with and without methyltestosterone: effects on endometrial histology and serum lipoproteins in postmenopausal women. *Obstet Gynecol* 1993;82:919-924.

53. Davis SR, Walker KZ, Strauss BJ. Effects of estradiol with and without testosterone on body composition and relationships with lipids in postmenopausal women. *Menopause* 2000;7:395-401.

54. Wisniewski A, Nguyen TT, Dobs AS. Evaluation of high-dose estrogen and high-dose estrogen plus methyltestosterone treatment on cognitive task performance in postmenopausal women. *Horm Res* 2002;58:150-155.

55. Somboonporn W, Davis S, for the National Health and Medical Research Council. Testosterone effects on the breast: implications for testosterone therapy for women. *Endocr Rev* 2004;25:374-388.

56. Key TJ, Appleby PN, Reeves GK, et al, for the Endogenous Hormones Breast Cancer Collaborative Group. Body mass index, serum sex hormones, and breast cancer risk in postmenopausal women. *J Natl Cancer Inst* 2003;95:1218-1226.

57. Dimitrakakis C, Jones RA, Liu A, Bondy CA. Breast cancer incidence in postmenopausal women using testosterone in addition to usual hormone therapy. *Menopause* 2004;11:531-535.

58. Dennerstein L, Leher P, Burger H. The relative effects of hormones and relationship factors on sexual function of women through the natural menopausal transition. *Fertil Steril* 2005;84:174-180.

59. Vermeulen A. The hormonal activity of the postmenopausal ovary. *J Clin Endocrinol Metab* 1976;42:247-253.

60. Vermeulen A, Verdonck L, Kaufman JM. A critical evaluation of simple methods for the estimation of free testosterone in serum. *J Clin Endocrinol Metab* 1999;84:3666-3672.

61. Rinaldi S, Geay A, Dechaud H, et al. Validity of free testosterone and free estradiol determinations in serum samples from postmenopausal women by theoretical calculations. *Cancer Epidemiol Biomarkers Prev* 2002; 11:1065-1071.

62. Södergard R, Backstrom T, Shanbhag V, Carstensen H. Calculation of free and bound fractions of testosterone and estradiol-17 beta to human plasma proteins at body temperature. *J Steroid Biochem* 1982;16:801-810.

63. Floter A, Carlstrom K, von Schoultz B, Nalthorst-Boos J. Administration of testosterone undecanoate in postmenopausal women: effects on androgens, estradiol, and gonadotrophins. *Menopause* 2000;7:251-256.

64. Slater CC, Souter I, Zhang C, Guan C, Stanczyk FZ, Mishell DR. Pharmacokinetics of testosterone after percutaneous gel or buccal administration. *Fertil Steril* 2001; 76:32-37.

65. Swerdloff RS, Wang C, Cunningham G, et al. Long-term pharmacokinetics of transdermal testosterone gel in hypogonadal men. *J Clin Endocrinol Metab* 2000;85: 4500-4510.

66. Rolf C, Knie U, Lemmnitz G, Nieschlag E. Interpersonal testosterone transfer after topical application of a newly developed testosterone gel preparation. *Clin Endocrinol (Oxf)* 2002;56:637-641.

**Subscription
Satisfaction**

We want you to be completely satisfied with your subscription to *Menopause Management*. Please contact us if your address has changed or if there is any question about your subscription.

Write to:

**Menopause Management
HealthCom Media
4259 W. Swamp Road,
Suite 408
Doylestown, PA 18901**

Or fax to:

215-489-7007